KalVista Pharmaceuticals (KALV) Assets Average (2015 - 2025)

KalVista Pharmaceuticals (KALV) has 11 years of Assets Average data on file, last reported at $233.1 million in Q3 2025.

• For the quarter ending Q3 2025, Assets Average rose 7.04% year-over-year to $233.1 million; the trailing twelve-month figure through Jul 2025 stood at $233.1 million (up 7.04% YoY), and the FY2025 full-year result was $243.1 million, up 16.14% from the prior year.
• Assets Average fell to $233.1 million in Q3 2025, from $272.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $272.8 million in Q2 2025 to a low of $70.8 million in Q1 2021.
• A 5-year average of $194.9 million and a median of $193.1 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 34.11% in 2021 and soared 230.99% in 2022, its largest moves.
• Tracing KALV's Assets Average over 5 years: stood at $251.5 million in 2021, then plunged by 31.37% to $172.6 million in 2022, then fell by 13.35% to $149.5 million in 2023, then jumped by 52.35% to $227.8 million in 2024, then advanced by 2.33% to $233.1 million in 2025.
• Business Quant data shows KALV's Assets Average at $233.1 million in Q3 2025, $272.8 million in Q2 2025, and $227.8 million in Q4 2024.